Hepatitis C virus therapy: No one will be left behind.

Abstract

The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C treatment landscape in the last 4 years, providing cure rates over 95% with shorter duration of treatment and a very good safety profile. This gave access to treatment to almost all Hepatitis C virus (HCV)-infected patients. The launch of two pangenotypic fixed-dose combinations (FDCs) in 2017 was a step forward in hepatitis C treatment, by slightly increasing efficacy and more importantly allowing the treatment of patients without HCV genotyping, and in some cases without fibrosis assessment. New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows almost all HCV-infected patients to be cured.

• Authors: Marc Bourlière, Olivia Pietri
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 53 Issue 6 Pg. 755-760 (Jun 2019) ISSN: 1872-7913 [Electronic] Netherlands
• PMID: 30605721 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019. Published by Elsevier B.V.

Chemical References

• Antiviral Agents
• Drug Combinations

Topics

• Antiviral Agents (administration & dosage)
• Drug Combinations
• Drug Therapy, Combination (methods)
• Drug-Related Side Effects and Adverse Reactions (epidemiology, pathology)
• Hepacivirus (drug effects)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Treatment Outcome